AI versus AI: The emerging arms race over health insurance denials
As health insurers use AI to deny more claims, startups are turning to AI to make it easier to appeal denials, which often go uncontested.
Related Articles
Krispy Kreme orders across the US disrupted after cyberattack
Wider details about the hole truth are still unknown
Does Male HPV Infection Affect Fertility?
This Medical News article discusses new research on how HPV infection in men may affect sperm.
Probabilistic weather forecasting with machine learning
Nature – GenCast, a probabilistic weather model using artificial intelligence for weather forecasting, has greater skill and speed than the top operational medium-range weather forecast…
Trump taps Andrew Ferguson to succeed Lina Khan at Federal Trade Commission
President-elect Donald Trump is picking Andrew Ferguson as Federal Trade Commission (FTC) chair, replacing Lina Khan. | Trump will appoint FTC commissioner Andrew Ferguson as…
Patients Couldn’t Pay Their Utility Bills. One Hospital Turned to Solar Power for Help. – KFF Health News
Doctors in Boston got tired of writing letters to utility companies asking for assistance for their medically vulnerable patients who need power and heat to…
Back to top
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Unhealthy, Ultra-processed Foods Now Half of Calories Americans Eat at Home
THURSDAY, Dec. 12, 2024 (HealthDay News) — Unhealthy ultra-processed foods have wormed their way into American kitchens, likely harming people’s health for dec
Ignaz Semmelweis Institut nimmt seine Arbeit auf
Mit Anfang 2025 nimmt das neue Ignaz Semmelweis Institut seine Arbeit auf. Diese Einrichtung auf dem Gebiet der Infektionsforschung ist ein Zusammenschluss der MedUni Wien,…
Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds
Report: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815 million in 2023.
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
This randomized noninferiority trial assesses the effect of a strategy of active monitoring vs guideline-concordant care on 2-year risk of ipsilateral invasive breast cancer among…